Alto Neuroscience, Inc.
Alto Neuroscience, Inc. (NASDAQ: ALTO) is a clinical-stage biopharmaceutical company dedicated to redefining psychiatry through precision medicine and personalized treatment approaches. The company's website is www.altoneuroscience.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Alto Neuroscience, Inc. does
In the company’s own words
Alto Neuroscience, Inc. (NASDAQ: ALTO) is a clinical-stage biopharmaceutical company dedicated to redefining psychiatry through precision medicine and personalized treatment approaches. The company's website is www.altoneuroscience.com.
Alto develops its product pipeline using a proprietary Precision Psychiatry Platform that leverages neurobiology and advanced data science to identify brain-based biomarkers that predict which patients are most likely to respond to specific treatments. This platform integrates neurocognitive assessments, electroencephalography (EEG) data, wearable device information, and genetic samples, employing machine learning and quantitative analytics to discover reproducible biomarkers suitable for clinical practice. The platform has been demonstrated across more than 70 clinical sites with over 2,000 participants.
The company's clinical-stage pipeline consists of seven assets addressing high-need psychiatric and neurological indications. ALTO-207, the most advanced program, is a fixed-dose combination of pramipexole and ondansetron being developed for treatment-resistant depression. ALTO-300, an agomelatine-based adjunctive treatment for major depressive disorder, is in Phase 2b trials with topline data expected in mid-2026. ALTO-100, targeting bipolar depression, and ALTO-101, a transdermal phosphodiesterase 4 inhibitor for cognitive impairment associated with schizophrenia, are also in Phase 2b development. Additional programs include ALTO-203 for depression with anhedonia, ALTO-202 for major depressive disorder, and ALTO-208 for Parkinson's disease.
Founded in 2019, Alto operates with internal clinical operations and software development expertise, enabling simultaneous multi-study execution and cost efficiency. The company estimates its portfolio addresses potential opportunities across more than 25 million patients in the United States alone. Alto maintains a clinical-stage operational model focused on biomarker discovery and validation, with plans to selectively partner product candidates with global pharmaceutical companies to maximize value while potentially establishing internal commercial capabilities for targeted indications.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- MOUNTAIN VIEW, CA
- Fiscal year end
- December
- CIK
- 1999480
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Alto Neuroscience, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Alto Neuroscience, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Alto Neuroscience, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Alto Neuroscience, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Alto Neuroscience, Inc.'s last four quarterly filings that the numbers alone won't show?”